$AKBA
Akebia Therapeutics, Inc. Stock $akba

$akba Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000162828022013318 Filed on May 09, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$61.70M	$52.30M
YoY Change	17.96%	-40.88%
Cost Of Revenue	$31.34M	$34.61M
YoY Change	-9.43%	24.87%
Gross Profit	$30.36M	$17.70M
YoY Change	71.52%	-70.87%
Gross Profit Margin	49.2%	33.84%
Selling, General & Admin	$44.33M	$41.33M
YoY Change	7.26%	8.81%
% of Gross Profit	146.03%	233.52%
Research & Development	$43.83M	$40.61M
YoY Change	7.93%	-50.01%
% of Gross Profit	144.4%	229.47%
Depreciation & Amortization	$9.428M	$9.520M
YoY Change	-0.97%	1713.33%
% of Gross Profit	31.06%	53.79%
Operating Expenses	$88.85M	$82.63M
YoY Change	7.52%	-31.08%
Operating Profit	-$58.49M	-$64.94M
YoY Change	-9.92%	9.83%
Interest Expense	-$5.062M	-$4.805M
YoY Change	5.35%	143.66%
% of Operating Profit
Other Income/Expense, Net	$1.134M	$161.0K
YoY Change	604.35%	-109.93%
Pretax Income	-$62.42M	-$69.60M
YoY Change	-10.31%	14.57%
Income Tax
% Of Pretax Income
Net Earnings	-$62.42M	-$69.58M
YoY Change	-10.29%	14.54%
Net Earnings / Revenue	-101.17%	-133.03%
Basic Earnings Per Share	-$0.35	-$0.45
Diluted Earnings Per Share	-$0.35	-$0.45
COMMON SHARES
Basic Shares Outstanding	179.6M shares	153.8M shares
Diluted Shares Outstanding	179.6M shares	153.8M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$174.6M	$272.8M
YoY Change	-36.01%	136.4%
Cash & Equivalents	$174.6M	$252.8M
Short-Term Investments		$20.00M
Other Short-Term Assets	$24.12M	$12.20M
YoY Change	97.71%	40.23%
Inventory	$39.42M	$44.81M
Prepaid Expenses
Receivables	$64.58M	$35.23M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$302.7M	$365.0M
YoY Change	-17.08%	7.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.451M	$8.168M
YoY Change	-21.02%	-17.12%
Goodwill	$55.10M	$55.10M
YoY Change	0.0%	0.09%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$39.42M	$39.64M
YoY Change	-0.55%	-44.89%
Total Long-Term Assets	$232.7M	$263.7M
YoY Change	-11.76%	-41.0%
TOTAL ASSETS
Total Short-Term Assets	$302.7M	$365.0M
Total Long-Term Assets	$232.7M	$263.7M
Total Assets	$535.4M	$628.7M
YoY Change	-14.85%	-20.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.47M	$30.54M
YoY Change	-36.25%	-43.84%
Accrued Expenses	$109.7M	$123.9M
YoY Change	-11.49%	-0.8%
Deferred Revenue	$10.44M	$18.25M
YoY Change	-42.8%	-47.68%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$97.85M
YoY Change
Total Short-Term Liabilities	$253.9M	$172.7M
YoY Change	47.04%	-19.37%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$96.61M
YoY Change	-100.0%	26.99%
Other Long-Term Liabilities	$77.74M	$53.62M
YoY Change	45.0%	-46.97%
Total Long-Term Liabilities	$77.74M	$150.2M
YoY Change	-48.25%	97.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$253.9M	$172.7M
Total Long-Term Liabilities	$77.74M	$150.2M
Total Liabilities	$509.2M	$414.8M
YoY Change	22.76%	42.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.523B	-$1.247B
YoY Change	22.11%	45.89%
Common Stock	$1.549B	$1.461B
YoY Change	6.02%	16.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$26.12M	$213.9M
YoY Change
Total Liabilities & Shareholders Equity	$535.4M	$628.7M
YoY Change	-14.85%	-20.19%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$62.42M	-$69.58M
YoY Change	-10.29%	14.54%
Depreciation, Depletion And Amortization	$9.428M	$9.520M
YoY Change	-0.97%	1713.33%
Cash From Operating Activities	-$21.62M	-$70.75M
YoY Change	-69.44%	-21.03%
INVESTING ACTIVITIES
Capital Expenditures	$114.0K	$59.00K
YoY Change	93.22%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$20.00M
YoY Change	-100.0%	7900.0%
Cash From Investing Activities	-$114.0K	$19.94M
YoY Change	-100.57%	8039.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$47.55M	$74.48M
YoY Change	-36.16%	29.87%
NET CHANGE
Cash From Operating Activities	-$21.62M	-$70.75M
Cash From Investing Activities	-$114.0K	$19.94M
Cash From Financing Activities	$47.55M	$74.48M
Net Change In Cash	$25.81M	$23.67M
YoY Change	9.04%	-173.98%
FREE CASH FLOW
Cash From Operating Activities	-$21.62M	-$70.75M
Capital Expenditures	$114.0K	$59.00K
Free Cash Flow	-$21.73M	-$70.81M
YoY Change	-69.3%	-20.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8756903
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	174562000	USD
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001517022
CY2022Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2022Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-36352
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	AKEBIA THERAPEUTICS, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2022Q1	dei	City Area Code CityAreaCode	617
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	245 First Street
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	871-2098
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.00001 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	AKBA
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	183533075	shares
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	50875000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	24121000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	33140000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	149800000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	39422000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	38195000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	64582000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	302687000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	272010000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6451000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6754000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32631000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33852000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	55053000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	55053000	USD
CY2022Q1	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	99116000	USD
CY2021Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	108127000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	39418000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	32581000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	49754000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	109660000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	104456000	USD
CY2022Q1	us-gaap	Assets Assets	535356000	USD
CY2021Q4	us-gaap	Assets Assets	525550000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	19466000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	33588000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10440000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	20906000	USD
CY2022Q1	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	16500000	USD
CY2021Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	0	USD
CY2022Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	97848000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	97543000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	253914000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	256493000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	65356000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	21474000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	33703000	USD
CY2022Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	1110000	USD
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1820000	USD
CY2022Q1	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	55095000	USD
CY2021Q4	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	53079000	USD
CY2022Q1	us-gaap	Contract With Customer Refund Liability Noncurrent ContractWithCustomerRefundLiabilityNoncurrent	23441000	USD
CY2021Q4	us-gaap	Contract With Customer Refund Liability Noncurrent ContractWithCustomerRefundLiabilityNoncurrent	0	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	77743000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	82525000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	509240000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	449094000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	183386035	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	183386035	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	177000963	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	177000963	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1548880000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1536800000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1522772000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1460351000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	26116000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	76456000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	535356000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	525550000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	61699000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52304000	USD
CY2022Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	22333000	USD
CY2021Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	25595000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	9011000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	9011000	USD
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	31344000	USD
CY2021Q1	us-gaap	Cost Of Revenue CostOfRevenue	34606000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43833000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40611000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	44327000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	41328000	USD
CY2022Q1	akba	License Expense LicenseExpense	688000	USD
CY2021Q1	akba	License Expense LicenseExpense	695000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	88848000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	82634000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-58493000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-64936000	USD
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-5062000	USD
CY2021Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4805000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1134000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	161000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-62421000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-69580000	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	179599045	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	179599045	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	153820809	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153820809	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-62421000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-69580000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-62421000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-69584000	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	247618000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	29498000	USD
CY2021Q1	akba	Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan	367000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5992000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-69580000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	213891000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	76456000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7178000	USD
CY2022Q1	akba	Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan	367000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4536000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-62421000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	26116000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-62421000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-69580000	USD
CY2022Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	417000	USD
CY2021Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	513000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9011000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9011000	USD
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	11000	USD
CY2022Q1	akba	Contractual Arrangement Royalties Agreement Noncash Interest Expense Income ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome	2345000	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Noncash Interest Expense Income ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome	2162000	USD
CY2022Q1	akba	Contractual Arrangement Royalties Agreement Noncash Royalty Revenue ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue	329000	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Noncash Royalty Revenue ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue	20000	USD
CY2022Q1	akba	Noncash Interest Expense NoncashInterestExpense	246000	USD
CY2021Q1	akba	Noncash Interest Expense NoncashInterestExpense	229000	USD
CY2022Q1	us-gaap	Straight Line Rent StraightLineRent	557000	USD
CY2021Q1	us-gaap	Straight Line Rent StraightLineRent	494000	USD
CY2022Q1	akba	Fair Value Adjustment To Inventory FairValueAdjustmentToInventory	0	USD
CY2021Q1	akba	Fair Value Adjustment To Inventory FairValueAdjustmentToInventory	21575000	USD
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	5344000	USD
CY2021Q1	us-gaap	Inventory Write Down InventoryWriteDown	5075000	USD
CY2022Q1	akba	Excess Inventory Purchase Commitments Expense Reversal ExcessInventoryPurchaseCommitmentsExpenseReversal	-773000	USD
CY2021Q1	akba	Excess Inventory Purchase Commitments Expense Reversal ExcessInventoryPurchaseCommitmentsExpenseReversal	-8945000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4536000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5992000	USD
CY2022Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-710000	USD
CY2021Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	80000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13707000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8380000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5247000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	19193000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-9019000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2268000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-3297000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1361000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7358000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4912000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4426000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4877000	USD
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	616000	USD
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	407000	USD
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	33416000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3007000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-3191000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21620000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-70746000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	114000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	59000	USD
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	20000000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-114000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19941000	USD
CY2022Q1	akba	Proceeds From Contractual Arrangement Royalties Agreement Sale Of Future Royalties ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties	0	USD
CY2021Q1	akba	Proceeds From Contractual Arrangement Royalties Agreement Sale Of Future Royalties ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties	44783000	USD
CY2022Q1	akba	Proceeds From Refund Liability To Contract With Customer ProceedsFromRefundLiabilityToContractWithCustomer	40000000	USD
CY2021Q1	akba	Proceeds From Refund Liability To Contract With Customer ProceedsFromRefundLiabilityToContractWithCustomer	0	USD
CY2022Q1	akba	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	7178000	USD
CY2021Q1	akba	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	29327000	USD
CY2022Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	367000	USD
CY2021Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	367000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	47545000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	74477000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	25811000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23672000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	151839000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231132000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	177650000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	254804000	USD
CY2022Q1	akba	Deferred Unpaid Offering Costs DeferredUnpaidOfferingCosts	0	USD
CY2021Q1	akba	Deferred Unpaid Offering Costs DeferredUnpaidOfferingCosts	171000	USD
CY2022Q1	us-gaap	Nature Of Operations NatureOfOperations	Nature of Organization and Operations<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Akebia Therapeutics, Inc., referred to as Akebia or the Company, was incorporated in the State of Delaware in 2007. Akebia is a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease. The Company has one commercial product, Auryxia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ferric citrate), which is approved by the U.S. Food and Drug Administration, or FDA, and marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with chronic kidney disease, or CKD, on dialysis, or DD-CKD, and the treatment of iron deficiency anemia, or IDA, in adult patients with CKD not on dialysis, or NDD-CKD. Ferric citrate is also approved and marketed in Japan as an oral treatment for IDA in adult patients for the improvement of hyperphosphatemia in such patients with DD-CKD and NDD-CKD under the trade name Riona (ferric citrate hydrate).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Vadadustat, the Company’s lead investigational product candidate, is an investigational oral hypoxia-inducible factor prolyl hydroxylase, or HIF-PH, inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. On March 29, 2022, the Company received a complete response letter, or CRL, from the FDA. The CRL provided that the FDA had completed its review of the Company's new drug application, or NDA, for vadadustat for the treatment of anemia due to CKD in adult patients and had determined that it could not approve the NDA in its present form. The Company is discussing the details of the CRL with the Company's collaboration partners. The Company’s collaboration partner, Otsuka Pharmaceutical Co. Ltd., or Otsuka, submitted a Marketing Authorization Application, or MAA, for vadadustat for the treatment of anemia due to CKD in adult patients with DD-CKD and NDD-CKD to the European Medicines Agency, or EMA, in October 2021</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Vadadustat is approved in Japan as a treatment for anemia due to CKD in both DD-CKD and NDD-CKD patients under the trade name Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and marketed and sold in Japan by Mitsubishi Tanabe Pharma Corporation, or MTPC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company continues to explore additional development opportunities to expand its pipeline and portfolio of novel therapeutics. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has devoted most of its resources to research and development, including its preclinical and clinical development activities, commercializing Auryxia, and providing general and administrative support for these operations. The Company began recording revenue from the U.S. sales of Auryxia and revenue from sublicensing rights to Auryxia in Japan from the Company’s Japanese partners, Japan Tobacco, Inc. and its subsidiary Torii Pharmaceutical Co., Ltd., collectively JT and Torii, in December 2018. Additionally, following regulatory approval of vadadustat in Japan, the Company began recognizing royalty revenues from MTPC from the sale of Vafseo in August 2020. In February 2021, the Company entered into a royalty interest acquisition agreement with HealthCare Royalty Partners IV, L.P., or HCR, or the Royalty Agreement, whereby the Company sold its right to receive royalties and sales milestones under its Collaboration Agreement with MTPC, or the MTPC Agreement, subject to certain caps and other terms and conditions (see Note 5 for additional information). The Company has not generated a profit to date and may never generate profits from product sales. Vadadustat and the Company’s other potential product candidates are subject to long development cycles, and the Company may be unsuccessful in its efforts to develop, obtain marketing approval for or market vadadustat and its other potential product candidates. If the Company does not successfully commercialize Auryxia, vadadustat, if approved, or any other potential product candidate, it may be unable to achieve profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s management completed its going concern assessment in accordance with Accounting Standards Codification, or ASC, 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, or ASC 205-40. Pursuant to the requirements of ASC 205-40, the Company’s management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">When substantial doubt exists under this methodology, the Company’s management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of the Company’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of March 31, 2022, the Company had cash and cash equivalents of approximately $174.6 million. The Company believes that its cash resources will be sufficient to allow the Company to fund its current operating plan through at least the next twelve months from the filing of this Quarterly Report on Form 10-Q. However, the Company's operating plan includes assumptions pertaining to cost avoidance measures and the reduction of overhead costs that would result from the planned amendment of certain contractual arrangements, including with certain supply and collaboration partners, and the reduction of certain infrastructure costs. Therefore, because these cost avoidance initiatives and certain other elements of the Company's operating plan are outside of its control, including the amendment of certain contractual arrangements, including with supply and collaboration partners, and the reduction of certain infrastructure costs, there is uncertainty as to whether the Company's cash resources will be adequate to support its operations for a period through at least the next twelve months from the date of issuance of these financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, on February 18, 2022, the Company and BioPharma Credit PLC, or the Collateral Agent, BPCR Limited Partnership, as a Lender, and BioPharma Credit Investments V (Master) LP, as a Lender, entered into the First Amendment and Waiver, or the First Amendment and Waiver, which amends and waives certain provisions of the Loan Agreement, dated November 11, 2019 (see Note 10). Pursuant to the Loan Agreement, as amended, the Company’s Quarterly Reports on Form 10-Q for the fiscal quarters ending June 30, 2022 and September 30, 2022, and its future Annual Reports on Form 10-K, must not be subject to any qualification as to going concern. If the Company does not satisfy the covenant as to going concern in any of these filings, the Company will be in default under the Loan Agreement. If an event of default occurs and is continuing under the Loan Agreement, the Collateral Agent is entitled to take enforcement action, including acceleration of amounts due under the Loan Agreement, which the Company may not have the available cash resources to repay at such time. There is also uncertainty as to whether or not the Company will meet its quarterly and annual debt covenants under the Loan Agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the financial statements are issued. Management’s plans to alleviate the conditions that raise substantial doubt through cost avoidance measures, including amending certain contractual arrangements, and deprioritizing and cancelling certain infrastructure activities for the Company to continue as a going concern for a period of twelve months from the date the financial statements are issued. However, the Company has concluded that the likelihood that its plan to extend its cash runway from one or more of these approaches will be successful, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements. If conditions that raise substantial doubt regarding the Company's ability to continue as a going concern still exist as of the filing of the Company's Quarterly Report on Form 10-Q for the quarter ending June 30, 2022, the Company will be in default under its Loan Agreement, as amended.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities, other than obligations under the Loan Agreement classified as current, that might result from the outcome of the uncertainties described above.</span></div>
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	174600000	USD
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: prepaid and accrued research and development expense, operating lease assets and liabilities, derivative liabilities, refund liabilities to customers, other non-current liabilities, including the excess purchase commitment liability, stock-based compensation expense, product and collaboration revenues including various rebates and reserves related to product sales, non-cash interest expense on the liability related to sale of future royalties, inventories, income taxes, intangible assets and goodwill. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</span></div>
CY2021Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	28378000	USD
CY2022Q1	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	25394000	USD
CY2022Q1	akba	Valuation Allowances And Reserves Adjustments Related To Prior Period Sales ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales	647000	USD
CY2022Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	26249000	USD
CY2022Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	28170000	USD
CY2020Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	41363000	USD
CY2021Q1	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	38965000	USD
CY2021Q1	akba	Valuation Allowances And Reserves Adjustments Related To Prior Period Sales ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales	-1238000	USD
CY2021Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	33661000	USD
CY2021Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	45429000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10440000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	65356000	USD
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	75796000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	6602000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5382000	USD
CY2022Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
CY2021Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q1	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	16500000	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Maximum Annual Royalty Payout Capacity ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity	13000000	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Maximum Aggregate Royalty Payout Capacity ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity	150000000	USD
CY2021Q1	akba	Proceeds From Contractual Arrangement Royalties Agreement Sale Of Future Royalties ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties	44800000	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	44800000	USD
CY2022Q1	akba	Contractual Arrangement Royalties Agreement Interest Rate Effective Percentage ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage	0.177
CY2021Q4	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	53079000	USD
CY2022Q1	akba	Contractual Arrangement Royalties Agreement Royalties Earned And Payable ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable	329000	USD
CY2022Q1	akba	Contractual Arrangement Royalties Agreement Noncash Interest Expense Income ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome	2345000	USD
CY2022Q1	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	55095000	USD
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	1820000	USD
CY2022Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-710000	USD
CY2022Q1	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	1110000	USD
CY2022Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	678000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1763000	USD
CY2022Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	74025000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	62635000	USD
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	8207000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	14661000	USD
CY2022Q1	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	82910000	USD
CY2021Q4	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	79059000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	39422000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	38195000	USD
CY2022Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	43488000	USD
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	40864000	USD
CY2022Q1	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	82910000	USD
CY2021Q4	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	79059000	USD
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	5300000	USD
CY2021Q1	us-gaap	Inventory Write Down InventoryWriteDown	5100000	USD
CY2022Q1	akba	Inventory Adjustments To Previous Reserves InventoryAdjustmentsToPreviousReserves	3200000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	213603000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	114487000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	99116000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	213603000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	105476000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	108127000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9000000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	55100000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	55100000	USD
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2022Q1	akba	Accrued Product Revenue Allowances Current AccruedProductRevenueAllowancesCurrent	26236000	USD
CY2021Q4	akba	Accrued Product Revenue Allowances Current AccruedProductRevenueAllowancesCurrent	26624000	USD
CY2022Q1	akba	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	16710000	USD
CY2021Q4	akba	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	14036000	USD
CY2022Q1	akba	Collaborative Arrangement Accrued Liability CollaborativeArrangementAccruedLiability	28019000	USD
CY2021Q4	akba	Collaborative Arrangement Accrued Liability CollaborativeArrangementAccruedLiability	22654000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7130000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15863000	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4763000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4802000	USD
CY2022Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3175000	USD
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3472000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2711000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1899000	USD
CY2022Q1	akba	Accrued Commercial Manufacturing Current AccruedCommercialManufacturingCurrent	3884000	USD
CY2021Q4	akba	Accrued Commercial Manufacturing Current AccruedCommercialManufacturingCurrent	3843000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	17032000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11263000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	109660000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	104456000	USD
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	177000963	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	183386035	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	177000963	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	183386035	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1800000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1700000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1800000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1800000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	5502000	USD
CY2022Q1	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	1370000	USD
CY2022Q1	akba	Lessee Operating Lease Liability Payments Net Reminder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear	4132000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6954000	USD
CY2022Q1	akba	Lessee Operating Lease Liability Payments Due Net Year Two LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo	8167000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8293000	USD
CY2022Q1	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	307000	USD
CY2022Q1	akba	Lessee Operating Lease Liability Payments Due Net Year One LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne	6647000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8167000	USD
CY2022Q1	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	0	USD
CY2022Q1	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	0	USD
CY2022Q1	akba	Lessee Operating Lease Liability Payments Due Net Year Three LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree	8293000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6571000	USD
CY2022Q1	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	0	USD
CY2022Q1	akba	Lessee Operating Lease Liability Payments Due Net Year Four LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour	6571000	USD
CY2022Q1	akba	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	12200000	USD
CY2022Q1	akba	Lessor Operating Lease Payment To Be Received Due After Year Four LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour	0	USD
CY2022Q1	akba	Lessee Operating Lease Liability Payments Due Net After Year Four LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour	12200000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	47687000	USD
CY2022Q1	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	1677000	USD
CY2022Q1	akba	Lessee Operating Lease Liability Payments Due Net LesseeOperatingLeaseLiabilityPaymentsDueNet	46010000	USD
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19970534	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18402397	shares
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	47687000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10006000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	37681000	USD
CY2022Q1	akba	Excess Inventory Purchase Commitments Expense Reversal ExcessInventoryPurchaseCommitmentsExpenseReversal	-800000	USD
CY2022Q1	akba	Inventory Adjustments To Previous Reserves InventoryAdjustmentsToPreviousReserves	3200000	USD
CY2022Q1	akba	Purchase Committed Program Remaining Contract Costs PurchaseCommittedProgramRemainingContractCosts	4700000	USD
CY2022Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross	211900000	USD

Files In Submission

Name	View Source	Status
0001628280-22-013318-index-headers.html	Edgar Link	pending
0001628280-22-013318-index.html	Edgar Link	pending
0001628280-22-013318.txt	Edgar Link	pending
0001628280-22-013318-xbrl.zip	Edgar Link	pending
akba-20220331.htm	Edgar Link	pending
akba-20220331.xsd	Edgar Link	pending
akba-20220331_cal.xml	Edgar Link	unprocessable
akba-20220331_def.xml	Edgar Link	unprocessable
akba-20220331_htm.xml	Edgar Link	completed
akba-20220331_lab.xml	Edgar Link	unprocessable
akba-20220331_pre.xml	Edgar Link	unprocessable
exhibit106-formofofficerre.htm	Edgar Link	pending
exhibit107-formoflettermic.htm	Edgar Link	pending
exhibit108-dellseparationa.htm	Edgar Link	pending
exhibit311-q12022.htm	Edgar Link	pending
exhibit312-q12022.htm	Edgar Link	pending
exhibit321-q12022.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AKBA
Akebia Therapeutics, Inc. Stock $akba

2022 Q1 Form 10-Q Financial Statement

#000162828022013318 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AKBA Akebia Therapeutics, Inc. Stock $akba

2022 Q1 Form 10-Q Financial Statement

#000162828022013318 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AKBA
Akebia Therapeutics, Inc. Stock $akba